In Discussion with the Industry: Existing and new conditions of the common pharmaceutical market in the EAEU. Prospects & Challenges – how pharma companies can adapt.
- Eurasian legal system. The interaction of national legislation and Union law in regulating the functioning of the common pharmaceutical market
- Issues of harmonization of national and Eurasian legislation – optimal approaches and pitfalls
- Problems of transition from national regulation to Eurasian. An experience of five countries
To what extent are EAEU member state systems ready for the new integrated registration process?
How will the Integrated IT system for the dossier submission function?
Will there be a different emphasis during future inspections? What problems could be encountered during inspections? Liberal or restrictive measures?
Drug licensing: cause and consequence; the influence on pharmaceutical business; Data protection with compulsory licensing
Possible suggestions of new balanced models for EAEU countries
In focus – Russia, Kazakhstan, Belarus
How ready manufacturers and regions are for drug labelling. Results, further proposals and initiatives, current implementation issues. Movement of goods between member states in the EAEU- what do the EAEU member states plan to do?